Observational studyFrontiers in public health2026
High-magnification inpatient cases under DIP payment reform: prevalence, cost burden, and risk factors in an NHC-administered hospital in China.
Observational study in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The nationwide rollout of Diagnosis-Intervention Packet (DIP) payment reform in China aims to enhance inpatient cost efficiency, yet high-magnification cases impose escalating financial burdens on tertiary hospitals. This study characterized the cost profiles and independent determinants of high-magnification cases under DIP to inform precision cost governance and medical insurance policy optimization. Methods: This retrospective observational study included 191,490 consecutive inpatient admissions from a National Health Commission-administered hospital in southern China (2024-2025). High-magnification cases were defined as actual hospitalization costs exceeding 2 times the standard DIP reimbursement benchmark in the present study. We analyzed their clinical features, cost composition, and multi-dimensional distribution. Multi-variable logistic regression adjusted for department-level fixed effects was applied to identify independent determinants. Results: A total of 17,929 (9.36%) high-magnification cases were identified. These cases had an average hospitalization cost of 65,366.0 Chinese Yuan (CNY), which was 2.38 times the overall average of 27,444.7 CNY, and a mean length of stay of 9.1 days. 49.42% of high-magnification cases resulted in DIP payment deficits, with a mean deficit of 1,492.1 CNY per case. The Charlson Comorbidity Index (CCI) fluctuated between 1.8 and 2.0 during the study period. Using multivariate logistic regression, the confidence intervals (CI) and odds ratios (OR) of influencing factors were calculated. Independent positive predictors included length of stay (LOS) (OR = 1.139, 95% CI 1.136-1.143), CCI (OR = 1.068, 95% CI 1.057-1.080), consumable cost proportion (OR = 1.029, 95% CI 1.026-1.031), and medication cost proportion (OR = 1.053, 95% CI 1.051-1.055). Subgroup analyses further suggested the highest high-magnification risk (all Conclusion: High-magnification DIP cases feature excessive resource consumption and high deficit rates. Prolonged LOS, consumables and medication costs are core drivers. Targeted cost control and optimized reimbursement benchmarks for complex conditions is beneficial for improving the utilization efficiency of medical insurance funds and maintaining the stable operation of hospitals while ensuring medical quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.